FVR and FIP Publications

FIP Research Synopsis

Published results from five independent clinical field and retrospective studies showed the benefit of Polyprenyl Immunostimulant™ in treating FIP.

All studies reported an increase in the expected survival times in cats with FIP and resolution of clinical pathologies. The treatment had no side effects (Legendre et al., 2017, Perkins, 2017, Cerna et al., 2022). However, concurrent treatment with corticosteroid drugs reduced the benefit of PI (Legendre et al., 2017). A combination of resolving anemia and normalization of A:G ratios during the PI treatment appeared to be a positive prognostic indicator for survival (Cerna et al., 2022). The treatment with PI alone or with PI in combination with antivirals resulted in the reduction of the levels of inflammatory marker alpha-1 acid glycoprotein in the patients (Addie et al., 2022).

2022 Retrospective Survival Analysis of Cats with Feline Infectious Peritonitis Treated with Polyprenyl Immunostimulant That Survived over 365 Days.

Černá, P.; Ayoob, A.; Baylor, C.; Champagne, E.; Hazanow, S.; Heidel, R.E.; Wirth, K.; Legendre, A.M.; Gunn-Moore, D.A.

Summary: This study adds important data about the successful treatment of FIP with PI; it shows that PI is beneficial in the management of this disease, and reports survival analysis of these cats. The MST was 2917 days (eight years) for those cats that survived to at least 365 days. A combination of resolving anemia and normalization of A:G ratios during the PI treatment appears to be a positive prognostic indicator for survival. This study demonstrates that PI is useful in the treatment of FIP.

Pathogens, 881.

Alpha-1 Acid Glycoprotein Reduction Differentiated Recovery from Remission in a Small Cohort of Cats Treated for Feline Infectious Peritonitis

Addie, D.D.; Silveira, C.; Aston, C.; Brauckmann, P.; Covell-Ritchie, J.; Felstead, C.; Fosbery, M.; Gibbins, C.; Macaulay, K.; McMurrough, J.; Pattison, E.; Robertson, E.

Summary: The paper has “shown that AGP measurement will be a useful parameter to assess their efficacy”. Four cats in the recovered group and one in the remission group were treated with PI only or a combination of PI and an antiviral.

Viruses 2022, 14, 744.

Polyprenyl Immunostimulant Treatment of Cats with Presumptive Non-Effusive Feline Infectious Peritonitis In a Field Study.

Legendre AM, Kuritz T, Galyon G, Baylor VM and Heidel RE

Summary: Sixty cats, diagnosed with dry FIP by primary care and specialist veterinarians and meeting the acceptance criteria were treated with PI without intentional selection of less severe cases. The survival time from the start of PI treatment in cats diagnosed with dry FIP showed that of the 60 cats with dry FIP treated with PI, 8 survived over 200 days, and 4 of 60 survived over 300 days. The survival times were significantly longer in cats not treated with corticosteroids concurrently with PI.

Front. Vet. Sci. 2017 4:7. doi: 10.3389/fvets.2017.00007

Feline Health Topics: Treatment for FIP Louisiana Vet. 27 (3): 10

Perkins, A.

Summary/Case report: a FIP patient treated with PI and has been surviving for over 2 years at the time of the publication.

Louisiana Vet. 2017, 27 (3): 10

Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis.

Legendre AM, Bartges JW

Summary: Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months.

JJFMS 2009 11, 624e626 doi:10.1016/j.jfms.2008.12.002

FVR and safety in cats research

Polyprenyl Immunostimulant in Feline Rhinotracheitis: Randomized Placebo-Controlled Experimental and Field Safety Studies.

Legendre AM, Kuritz T, Heidel RE and Baylor VM 2017

Summary: Data from a double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats (2 days to 15 years old) in 10 states, showed that PI was safe to use in cats.

Front. Vet. Sci. 2017 4:24. doi: 10.3389/fvets.2017.00024